Ginkgo Bioworks Holdings (DNA) Net Equity Issued and Repurchased (2020 - 2025)
Ginkgo Bioworks Holdings' (DNA) quarterly Net Equity Issued and Repurchased came in at $9.2 million in Q4 2025, up 137.19% on a QoQ basis from -$24.6 million in Q4 2022.
Ginkgo Bioworks Holdings (DNA) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $9.2 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.9 million (up 75.51% YoY) and the FY2025 annual result came in at $19.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $9.2 million in Q4 2025, from -$24.6 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $15.1 million in Q3 2021 to a low of -$24.6 million in Q4 2022.
- A 3-year average of -$1.6 million and a median of $7.6 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased surged 83.43% — and 2022, when it plunged 63.1%.
- Tracing DNA's Net Equity Issued and Repurchased over 3 years: stood at -$15.1 million in 2021, then plunged by 63.1% to -$24.6 million in 2022, then surged by 137.19% to $9.2 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $9.2 million (Q4 2025), -$24.6 million (Q4 2022), and $7.6 million (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.15 Mn |
| Dec 31, 2025 | 9.15 Mn |
| Dec 31, 2022 | -24.61 Mn |
| Dec 31, 2022 | -24.61 Mn |
| Sep 30, 2022 | 7.59 Mn |
| Sep 30, 2022 | 7.59 Mn |
| Dec 31, 2021 | -15.09 Mn |
| Dec 31, 2021 | -15.09 Mn |
| Sep 30, 2021 | 15.09 Mn |
| Sep 30, 2021 | 15.09 Mn |
| Dec 31, 2020 | -91.04 Mn |
| Dec 31, 2020 | -91.04 Mn |